Fosun Pharma's Unit Signs Co-Development, Licensing Options Deal With Clavis Bio

Reuters
2025.12.18 10:36
Dec 18 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS) : * SAYS UNIT SIGNS DEAL WITH CLAVIS BIO FOR CO-DEVELOPMENT AND EXCLUSIVE LICENSING OPTIONS * SAYS COULD RECEIVE UP TO $362.5 MILLION PER PROJECT IF CLAVIS BIO EXERCISES OPTION Source text Further company coverage: (600196.SS)
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer